Article Text

Download PDFPDF

5PSQ-033 Antiviral treatment discontinuation in patients with hepatitis b
  1. E Martinez,
  2. S Corrales,
  3. C Dean,
  4. A Codonal,
  5. P Tardaguila,
  6. GI Casarrubios,
  7. A Miranda,
  8. A Lazaro
  1. Hospital Universitario de Guadalajara, Hospital Pharmacy, Guadalajara, Spain


Background and Importance Studies suggest the safest strategy of treatment discontinuation with nucleos(t)ide analogues (NAs) against hepatitis B virus (HBV), is proposed after loss surface antigen (HBsAg). Evidence supports the possibility of discontinuing NAs in the following situations:

  • Patients with positive e antigen (HBeAg) without cirrhosis: after negativisation of HBV-DNA and HBeAg seroconversion, confirmed in 2 determinations separated by 3-6 months and after NAs at least 12 months.

  • Patients with negative HBeAg, without advanced fibrosis early in treatment: after negativisation of HBV-DNA for at least 3 years and HBsAg clearance (qHBsAg) ≤1000 IU/mL.

Aim and Objectives The objective was to characterise the population in treatment with NAs and analyse patients who met requirements for treatment discontinuation

Material and Methods Cross-sectional, descriptive, retrospective study of patients under active treatment with NAs between August 2020-August 2021.

Variables collected: demographic, NAs used, treatment duration and clinical (positive or negative HBeAg, HBeAg seroconversion, HBV-DNA, qHBsAg, degree of hepatic fibrosis, HBsAg loss, virological relapse (RV) (HBV-DNA>2000 IU/ml after treatment discontinuation).

Results We included 50 patients (70% men). Median age was 56 years (IQR: 48-66) and median of treatment duration was 66 months (IQR: 27-108). 62% were treated with tenofovir disoproxil fumarato and 38% with entecavir.

8% of patients had positive HBeAg without seroconversion and without negative HBV-DNA. 92% had negative HBeAg with seroconversion and negative DNA-HBV.

32% of patients had qHBsAg ≤1000 IU/ml, 28% ≥1000 IU/ml and 40% not determined. 30% of patients had advanced fibrosis.

In 12% of patients with positive HBsAg, treatment discontinuation could be considered. All of them had HBeAg negative, fibrosis F0-F1 at the beginning of treatment, negative HBV-DNA maintained at least 3 years and qHBsAg≤1000 IU/ml.

HBsAg loss occurred in 6% of patients who had not discontinued treatment and 16% of patients had to restart treatment for RV.

Conclusion and Relevance

  • Study population includes patients who meet criteria for treatment discontinuation.

  • Treatment discontinuation requires close follow-up to detect RV.

  • In patients with HBsAg loss, treatment was not discontinued due to advanced fibrosis.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.